Market Cap
$306.5M
INDP
Indaptus Therapeutics, Inc.
$2.35 ▲ +11.06%
Prev close $2.12Market cap$306.5M
12-mo target$10.00 (+191.5%)
High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on INDP right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Inst. Holders
8 funds
Inst. Value
$537.3K
Inst. Activity
2 buys / 0 sells
Insider Activity
$0.00 buy / $0.00 sell
Social Sentiment
75° Bullish
SEC Reports
13
Price chart 30d +101.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 22, 2026 short_volume
Sep 10, 2026 SEC Short Volume: INDP — 61.9% short (0.3M / 0.5M)
Short: 311,477 | Exempt: 37,909 | TRF Vol: 503,321 | Short Ratio: 61.9% | Off-exchange volume (dark
Indaptus Therapeutics entered into a stock purchase agreement for a $24M private placement of 20,338,974 shares, priced
8-K — Impact 7/10
Indaptus Therapeutics filed Amendment No. 1 to its August 31, 2026 prospectus supplement, correcting a clerical error in
424B5 — Impact 6/10
Indaptus Therapeutics entered into an amended and restated at-the-market offering agreement with H.C. Wainwright, enabli
8-K — Impact 5/10
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — DOUBLED
56,470 shares ($169.4K)
Jun 30, 2026 Inst.
MORGAN STANLEY — DOUBLED
8,936 shares ($26.8K)
Mar 23, 2026 Insider
Lazar David E. sold 700,000 shares
Director
Mar 23, 2026 Insider
Lazar David E. sold 196,800 shares
Director
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Nov 13, 2024 | Maxim Group | MAINTAIN | Buy | 43% |
| Oct 16, 2024 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jun 17, 2024 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Apr 15, 2024 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Sep 20, 2023 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 15, 2023 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 11, 2023 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 8, 2023 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 4, 2023 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Mar 20, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Aug 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jul 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Price targets
Where 1 covering analysts think INDP trades over the next 12 months.
$10.00 +191.5% upside Strong Buy
Current$3.43 Low$10.00 Median$10.00 High$10.00 1 analysts
$10.00$10.00
Analyst rating None as of Apr 28, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
75°
Bullish
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
13 SEC filing reports analyzed · 0 bullish, 10 bearish, 0 mixed, 3 neutral · avg impact 5.8/10.
BEARISH8-K7/10
Indaptus Therapeutics entered into a stock purchase agreement for a $24M private placement of 20,338
Sep 10, 2026
BEARISH424B56/10
Indaptus Therapeutics filed Amendment No. 1 to its August 31, 2026 prospectus supplement, correcting
Sep 4, 2026
BEARISH8-K5/10
Indaptus Therapeutics entered into an amended and restated at-the-market offering agreement with H.C
Sep 1, 2026
BEARISHEFFECT7/10
The SEC declared effective Indaptus Therapeutics' S-3 registration (File No. 333-298388) on August 2
Aug 26, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 22, 2026
short_volume
Short Volume: INDP — 61.9% short (0.3M / 0.5M)
Short: 311,477 | Exempt: 37,909 | TRF Vol: 503,321 | Short Ratio: 61.9% | Off-exchange volume (dark pool + OTC)
Sep 15, 2026
short_volume
Short Volume: INDP — 62.6% short (0.7M / 1.1M)
Short: 663,576 | Exempt: 6,708 | TRF Vol: 1,059,212 | Short Ratio: 62.6% | Off-exchange volume (dark pool + OTC)
Sep 14, 2026
short_volume
Short Volume: INDP — 62.7% short (0.4M / 0.7M)
Short: 443,134 | Exempt: 1,222 | TRF Vol: 706,408 | Short Ratio: 62.7% | Off-exchange volume (dark pool + OTC)
Sep 11, 2026
short_volume
Short Volume: INDP — 60.7% short (0.6M / 0.9M)
Short: 559,362 | Exempt: 15,641 | TRF Vol: 920,842 | Short Ratio: 60.7% | Off-exchange volume (dark pool + OTC)
Sep 10, 2026
short_volume
Short Volume: INDP — 57.3% short (1.1M / 2.0M)
Short: 1,148,569 | Exempt: 18,371 | TRF Vol: 2,004,368 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Current FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
Institutional ownership
Which big funds own INDP (from quarterly 13F filings) and who is adding or trimming.
8 institutional holders with $537.3K total value (384,977 shares) as of 2026-Q2. Top holders: GEODE, JANE, VANGUARD. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 56,470 | $169.4K | 31.5% | DOUBLED +109.1% |
| JANE STREET GROUP, LLC | 53,811 | $161.4K | 30.0% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 33,652 | $101.0K | 18.8% | — |
| VANGUARD FIDUCIARY TRUST CO | 13,967 | $41.9K | 7.8% | — |
| MILLENNIUM MANAGEMENT LLC | 11,586 | $34.8K | 6.5% | — |
| MORGAN STANLEY | 8,936 | $26.8K | 5.0% | DOUBLED +231.3% |
| UBS Group AG | 478 | $1.4K | 0.3% | DOUBLED +5677.3% |
| HRT FINANCIAL LP | 206,077 | $618.00 | 0.1% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 27,007 | 56,470 | +109.1% | $169.4K |
| MORGAN STANLEY | DOUBLED | 2,697 | 8,936 | +231.3% | $26.8K |
| UBS Group AG | DOUBLED | 502 | 29,002 | +5677.3% | $84.4K |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 82,118 | 124,967 | +52.2% | $68.7K |
| BANK OF AMERICA CORP /DE/ | ADD | 61 | 98 | +60.7% | $54.00 |
| UBS Group AG | NEAR_EXIT | 2,523 | 87 | -96.6% | $49.00 |
| UBS Group AG | DOUBLED | 522 | 2,523 | +383.3% | $2.1K |
| CITADEL ADVISORS LLC | TRIM | 22,210 | 15,390 | -30.7% | $19.1K |
| BANK OF AMERICA CORP /DE/ | ADD | 42 | 60 | +42.9% | $74.00 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
3 insiders, 9 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 23, 2026 | Lazar David E. | Director | SELL | 700,000 | — | — |
| Mar 23, 2026 | Lazar David E. | Director | SELL | 196,800 | — | — |
| Feb 26, 2026 | Jabbour Jerome D | Director | AWARD | 25,000 | — | — |
| Feb 11, 2026 | Meckler Jeffrey A | Co-Chief Executive Officer | AWARD | 1,519 | — | — |
| Feb 11, 2026 | Meckler Jeffrey A | Co-Chief Executive Officer | D | 1,519 | — | — |
| Feb 11, 2026 | Meckler Jeffrey A | Co-Chief Executive Officer | D | 3,033 | — | — |
| Feb 11, 2026 | Meckler Jeffrey A | Co-Chief Executive Officer | AWARD | 12,136 | — | — |
| Feb 11, 2026 | Meckler Jeffrey A | Co-Chief Executive Officer | D | 12,136 | — | — |
| Feb 11, 2026 | Meckler Jeffrey A | Co-Chief Executive Officer | AWARD | 3,033 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for INDP.
Shares short
916,352
Settlement Sep 15, 2026
Change vs prior
+331.5%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈0.7%
Estimate — not % of float
All INDP filing & press-release reports (13)
- 8-K reportSep 10, 2026
- 424B5 reportSep 4, 2026
- 8-K reportSep 1, 2026
- EFFECT reportAug 26, 2026
- S-3 reportAug 17, 2026
- 8-K reportAug 13, 2026
- EFFECT reportJul 20, 2026
- S-3 reportJun 26, 2026
- 8-K reportJun 25, 2026
- 8-K reportMay 15, 2026
- PRESS-RELEASE reportMay 15, 2026
- 8-K reportApr 23, 2026
- 8-K reportApr 3, 2026